Ionis Pharmaceuticals IONS Intangible Amortization
Intangible Amortization at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's intangible amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's intangible amortization?
- Ionis Pharmaceuticals (IONS) reported intangible amortization of $40K in Q1 2026.
- How has Ionis Pharmaceuticals's intangible amortization changed year-over-year?
- Ionis Pharmaceuticals's intangible amortization decreased by 34.4% year-over-year, from $61K to $40K.
- What is the long-term trend for Ionis Pharmaceuticals's intangible amortization?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's intangible amortization has grown at a -22.3% compound annual growth rate (CAGR), from $2.71M to $986K.
- What does intangible amortization mean?
- The non-cash expense of spreading the cost of intangible assets over their useful life.
- How do you interpret intangible amortization?
- An increase reflects higher levels of acquired intellectual property or recent business combinations.
- How does intangible amortization compare across companies?
- Standard for R&D-heavy firms like Ionis; peers with significant M&A activity will show higher levels of this expense.